Quick Answer
Lyell Immunopharma, Inc. reported Total Assets of $340.05 million for fiscal year 2025.
Lyell Immunopharma, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $340.05M | -30.7% |
| 2024 | $490.86M | -34.6% |
| 2023 | $750.03M | -20.0% |
| 2022 | $937.56M | -16.8% |
| 2021 | $1.13B | +24.1% |
| 2020 | $908.28M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $407.96M | -34.1% | +5.8% |
| June 30, 2025 | $385.45M | -41.1% | -10.3% |
| March 31, 2025 | $429.80M | -38.1% | -12.4% |
| December 31, 2024 | $490.86M | -34.6% | -20.7% |
| September 30, 2024 | $619.22M | -22.1% | -5.3% |
| June 30, 2024 | $654.14M | -21.7% | -5.8% |
| March 31, 2024 | $694.22M | -21.2% | -7.4% |
| December 31, 2023 | $750.03M | -20.0% | -5.7% |
- Lyell Immunopharma, Inc. showed a decrease of -30.7% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, Lyell Immunopharma, Inc.’s total assets has declined by 62.6% (from $908.28 million to $340.05 million).
- The most recent figure is from Lyell Immunopharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: